Evidence map›Paper›PMID 34765580›Full record

ArticleFrontiers in public health2021

SARS-CoV-2 Seroprevalence and Profiles Among Convalescents in Sichuan Province, China.

Lijun Zhou, Cheng Li, Huiping Yang, Heng Yuan, Ming Pan, Xiuwei Cheng, Chongkun Xiao, Xiaoyan Su, Yuanfang Zhu, Jianan Xu and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Lijun ZhouSichuan Center for Disease Control and Prevention, Chengdu, China.
Cheng LiDepartment of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Sichuan, China.
Huiping YangSichuan Center for Disease Control and Prevention, Chengdu, China.
Heng YuanSichuan Center for Disease Control and Prevention, Chengdu, China.
Ming PanSichuan Center for Disease Control and Prevention, Chengdu, China.
Xiuwei ChengSichuan Center for Disease Control and Prevention, Chengdu, China.
Chongkun XiaoSichuan Center for Disease Control and Prevention, Chengdu, China.
Xiaoyan SuLu County Center for Disease Control and Prevention, Luzhou, China.
Yuanfang ZhuGulin County Center for Disease Control and Prevention, Luzhou, China.
Jianan XuSichuan Center for Disease Control and Prevention, Chengdu, China.
Jianxiang TangDepartment of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Sichuan, China.
Xunbo DuChengdu Center for Disease Control and Prevention, Chengdu, China.
Huanwen PengDazhou Center for Disease Control and Prevention, Dazhou, China.
Xiao ChenNanchong Center for Disease Control and Prevention, Nanchong, China.
Tao HuangGuangan Center for Disease Control and Prevention, Guangan, China.
Hongxiu LiaoPanzhihua Center for Disease Control and Prevention, Panzhihua, China.
Deqiang XianLuzhou Center for Disease Control and Prevention, Luzhou, China.
HaoZhou WangMianyang Center for Disease Control and Prevention, Mianyang, China.
Wenwu LiuSuining Center for Disease Control and Prevention, Suining, China.
Ping ZhouYibin Center for Disease Control and Prevention, Yibin, China.
Zhengdong ZhangZigong Center for Disease Control and Prevention, Zigong, China.
Juan LiuNeijiang Center for Disease Control and Prevention, Neijiang, China.
Xianping WuSichuan Center for Disease Control and Prevention, Chengdu, China.
Tao ZhangDepartment of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralChinaHumansImmunoglobulin GSeroepidemiologic StudiesAntibodies, ViralImmunoglobulin Gassociated factorsconvalescentsdurationSARS-CoV-2seroprevalence

Identifiers

PMID34765580
PMCPMC8577692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.